Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, Foster D, Milstein S, Charisse K, Kuchimanchi S, Maier MA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A.

Nat Med. 2015 Apr 13. doi: 10.1038/nm.3847. [Epub ahead of print]

PMID:
25849132
2.

Macrophages retain hematopoietic stem cells in the spleen via VCAM-1.

Dutta P, Hoyer FF, Grigoryeva LS, Sager HB, Leuschner F, Courties G, Borodovsky A, Novobrantseva T, Ruda VM, Fitzgerald K, Iwamoto Y, Wojtkiewicz G, Sun Y, Da Silva N, Libby P, Anderson DG, Swirski FK, Weissleder R, Nahrendorf M.

J Exp Med. 2015 Apr 6;212(4):497-512. doi: 10.1084/jem.20141642. Epub 2015 Mar 23.

PMID:
25800955
3.

Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent N-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo.

Rajeev KG, Nair JK, Jayaraman M, Charisse K, Taneja N, O'Shea J, Willoughby JL, Yucius K, Nguyen T, Shulga-Morskaya S, Milstein S, Liebow A, Querbes W, Borodovsky A, Fitzgerald K, Maier MA, Manoharan M.

Chembiochem. 2015 Apr 13;16(6):903-8. doi: 10.1002/cbic.201500023. Epub 2015 Mar 18.

PMID:
25786782
4.

siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes.

Matsuda S, Keiser K, Nair JK, Charisse K, Manoharan RM, Kretschmer P, Peng CG, V Kel'in A, Kandasamy P, Willoughby JL, Liebow A, Querbes W, Yucius K, Nguyen T, Milstein S, Maier MA, Rajeev KG, Manoharan M.

ACS Chem Biol. 2015 Mar 2. [Epub ahead of print]

PMID:
25730476
5.

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.

Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, Taneja N, O'Shea J, Shaikh S, Zhang L, van der Sluis RJ, Jung ME, Akinc A, Hutabarat R, Kuchimanchi S, Fitzgerald K, Zimmermann T, van Berkel TJ, Maier MA, Rajeev KG, Manoharan M.

J Am Chem Soc. 2014 Dec 10;136(49):16958-61. doi: 10.1021/ja505986a. Epub 2014 Dec 1.

PMID:
25434769
6.

A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.

Gutschow P, Schmidt PJ, Han H, Ostland V, Bartnikas TB, Pettiglio MA, Herrera C, Butler JS, Nemeth E, Ganz T, Fleming MD, Westerman M.

Haematologica. 2015 Feb;100(2):167-77. doi: 10.3324/haematol.2014.116723. Epub 2014 Nov 25.

7.

Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus.

Kim YI, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J, Alvarez R, Hurwitz JL.

PLoS One. 2014 Nov 21;9(11):e113100. doi: 10.1371/journal.pone.0113100. eCollection 2014.

8.

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy.

Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, Nair JK, Akinc A, Barros SA, Kasperkovitz PV.

Mol Ther Nucleic Acids. 2014 Nov 18;3:e210. doi: 10.1038/mtna.2014.61.

PMID:
25405467
9.

"Complex" attention-deficit hyperactivity disorder, more norm than exception? Diagnoses and comorbidities in a developmental clinic.

Koolwijk I, Stein DS, Chan E, Powell C, Driscoll K, Barbaresi WJ.

J Dev Behav Pediatr. 2014 Nov-Dec;35(9):591-7. doi: 10.1097/DBP.0000000000000109.

PMID:
25343695
10.

Development of LC-MS methods for quantitation of hepcidin and demonstration of siRNA-mediated hepcidin suppression in serum.

Li S, Nakayama T, Akinc A, Wu SL, Karger BL.

J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:110-9. doi: 10.1016/j.vascn.2014.09.008. Epub 2014 Oct 2.

PMID:
25281793
11.

Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials.

Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, Bettencourt BR, Karsten V, Dyck PJ.

J Neurol Sci. 2014 Sep 15;344(1-2):121-8. doi: 10.1016/j.jns.2014.06.041. Epub 2014 Jun 27.

PMID:
25012480
12.

The roles of individual mammalian argonautes in RNA interference in vivo.

Ruda VM, Chandwani R, Sehgal A, Bogorad RL, Akinc A, Charisse K, Tarakhovsky A, Novobrantseva TI, Koteliansky V.

PLoS One. 2014 Jul 3;9(7):e101749. doi: 10.1371/journal.pone.0101749. eCollection 2014.

13.

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, Fenton OS, Zhang Y, Olejnik KT, Yesilyurt V, Chen D, Barros S, Klebanov B, Novobrantseva T, Langer R, Anderson DG.

Nat Commun. 2014 Jun 27;5:4277. doi: 10.1038/ncomms5277.

14.

Silencing of CCR2 in myocarditis.

Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva TI, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M.

Eur Heart J. 2014 Jun 20. pii: ehu225. [Epub ahead of print]

PMID:
24950695
15.

Technology: Investment suggests RNAi is on the up.

Maraganore J.

Nature. 2014 Jun 5;510(7503):35. doi: 10.1038/510035b. No abstract available.

PMID:
24899296
16.

RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.

Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, New MI, Liebow A, Fitzgerald K, Querbes W, Desnick RJ.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):7777-82. doi: 10.1073/pnas.1406228111. Epub 2014 May 12.

17.

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Dahlman JE, Barnes C, Khan OF, Thiriot A, Jhunjunwala S, Shaw TE, Xing Y, Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL, Yin H, Racie T, Dong Y, Jiang S, Seedorf D, Dave A, Singh Sandhu K, Webber MJ, Novobrantseva T, Ruda VM, Lytton-Jean AK, Levins CG, Kalish B, Mudge DK, Perez M, Abezgauz L, Dutta P, Smith L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M, Danino D, Tuder RM, von Andrian UH, Akinc A, Panigrahy D, Schroeder A, Koteliansky V, Langer R, Anderson DG.

Nat Nanotechnol. 2014 Aug;9(8):648-55. doi: 10.1038/nnano.2014.84. Epub 2014 May 11.

18.

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing.

Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M.

J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66. doi: 10.1016/j.jacc.2013.11.023. Epub 2013 Dec 18.

19.

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.

Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, Manoharan M, Akinc A, Maier MA, Cullis P, Madden TD, Hope MJ.

Mol Ther Nucleic Acids. 2013 Dec 17;2:e139. doi: 10.1038/mtna.2013.66.

20.

Exploiting endocytosis for nanomedicines.

Akinc A, Battaglia G.

Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a016980. doi: 10.1101/cshperspect.a016980. Review.

PMID:
24186069
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk